Organization

David J. Vachon, Ph.D., Chief Executive Officer

Dr. David Vachon, Ph.D., MBA, is a pharmaceutics and medical device entrepreneur with extensive experience in product development, engineering, and management. He has held key roles at St. Jude Medical, Minimed, and Medtronic, and served as CTO of Aegis Biosciences. Following a successful exit with Boston Scientific, he founded IASIS in Spokane, WA.

Mark R. Vachon, Vice President, Quality

Mark Vachon holds a B.S. in Biological Sciences and has more than 25 years of experience in the biotechnology field, including product development, quality control, and project management. He also has a background in food microbiology. He joined IASIS in 2017 as QC Manager and, since 2020, has served as a microbiologist and laboratory chemist at IASIS.

Business Advisors

IASIS advisors include Mr. Chris Rivera, Dr. Christopher Porter, and Mr. Jary Krauser. IASIS scientific advisory is provided by Dr. David Grainger.

Mr. Jary Krauser is the CEO of StratusG Consulting, based in Seattle, Washington. With over 20 years of executive experience, he serves a diverse range of clients across the life sciences, high-tech, and aerospace sectors.

Dr. Christopher H. Porter brings 40 years of experience in the medical device and biotechnology industries, with leadership roles at 3M, Johnson & Johnson, Pfizer, and early-stage medical companies. He has introduced over 35 medical products, holds 42 U.S. medical device patents, and now focuses on mentoring, supporting startups, and contributing to entrepreneurial education at Seattle University and the University of Washington.

Mr. Chris Rivera is President and CEO of Emulate Therapeutics in Seattle, Washington. He has 30 years of biotechnology leadership experience, including founding and leading Hyperion Therapeutics (acquired by Horizon Pharma), senior leadership at Tercica and Genzyme Therapeutics, and early contributions to the commercial development of Cephalon and Centocor.

Scientific Advisor

Dr. David Grainger is University Distinguished Professor and Chair of Bioengineering at the University of Utah, with additional appointments in Pharmaceutics, Orthopedics, and Chemistry. His research focuses on drug delivery, medical device and diagnostic performance, and nanomaterials toxicity. He also consults for the biomedical and pharmaceutical industries and has played a key role in commercializing six biotech startups.